Militia Capital Management LLC Makes New $863,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Militia Capital Management LLC purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the first quarter, HoldingsChannel.com reports. The fund purchased 34,500 shares of the company’s stock, valued at approximately $863,000.

Several other institutional investors have also modified their holdings of PRCT. Advisory Services Network LLC increased its stake in PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares in the last quarter. Osaic Holdings Inc. lifted its stake in PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares in the last quarter. ProShare Advisors LLC increased its position in shares of PROCEPT BioRobotics by 4.7% during the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after acquiring an additional 438 shares in the last quarter. California State Teachers Retirement System increased its position in shares of PROCEPT BioRobotics by 1.4% during the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after acquiring an additional 693 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT opened at $18.62 on Monday. The company’s 50-day moving average price is $22.39 and its two-hundred day moving average price is $25.15. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $51.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The stock has a market capitalization of $1.06 billion, a PE ratio of -10.23 and a beta of 0.89.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PRCT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Truist Financial reissued a “hold” rating and issued a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd. Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Piper Sandler reaffirmed an “overweight” rating and set a $35.00 price objective (up from $28.00) on shares of PROCEPT BioRobotics in a research report on Thursday, April 30th. Finally, UBS Group lowered PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of “Hold” and a consensus target price of $33.45.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.